Abstracts tagged "SLE"

Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…
Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting
Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India
Sarit Sekhar Pattanaik¹, Hafis Muhammed ², Amita Aggarwal ³, Able Lawrence ⁴, Vikas Agarwal ², Durga P Misra ², Latika Gupta ⁴ and Ramnath Misra ⁴, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²SGPGI, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…
Abstract Number: 1864 • 2019 ACR/ARP Annual Meeting
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Gabriela Schmajuk¹, Zara Izadi ², Michael Evans ³ and Jinoos Yazdany ⁴, ¹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ²UCSF Division of Rheumatology, San Francisco, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although multiple national quality measures focus on the management and safety of rheumatoid arthritis, few measures address the care of patients with SLE. We…
Abstract Number: 2555 • 2019 ACR/ARP Annual Meeting
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Konstantinos Tselios¹, Dafna Gladman ², Shadi Akhtari ³, Paula Harvey ³, Kate Hanneman ⁴ and Murray Urowitz ⁵, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial-induced cardiomyopathy (AMIC) is a hypertrophic cardiomyopathy with conduction system disorders, cardiac biomarker abnormalities and a short-term mortality of 45%. Data on the reversibility…
Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Chiao-Feng Cheng, Cheng-Hsun Lu, Song-Chou Hsieh and Ko-Jen Li, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…
Abstract Number: 1083 • 2018 ACR/ARHP Annual Meeting
Changes of Innate Lymphoid Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus and Its Correlations with Clinical Markers
Hui Chu, Xiaomei Li, zhen Tan, ruolan Wu, Xiangpei Li, xuan Fang, xu Zhen and Guosheng Wang, The first affiliated hospital of university of Science and Technology of China, Hefei, China
Background/Purpose: Innate Lymphoid Cells (ILCs) are a novel group of innate immune cells, according to the cytokine profile, they were divided into three major subsets:…
Abstract Number: 1856 • 2018 ACR/ARHP Annual Meeting
Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE Inception Cohort
Arielle Mendel, Sasha Bernatsky and Evelyne Vinet, Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Because aspirin reduces the risk of preeclampsia in high-risk pregnancies by more than half, best practice guidelines recommend that aspirin be initiated in pregnant…
Abstract Number: 2132 • 2018 ACR/ARHP Annual Meeting
All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE
Suying Li, Yi Peng, Tingting Gong, Kimberly M. Nieman and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at higher risk of complications such as heart attack and renal disease. We aimed to estimate all-cause…
Abstract Number: 2853 • 2018 ACR/ARHP Annual Meeting
A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity
William D. Shipman^1,2,3, Susan Chyou¹, Anusha Ramanathan¹, Peter M. Izmirly⁴, Sneh Sharma⁵, Tania Pannellini⁶, Dragos Dasoveanu¹, Xiaoping Qing⁷, Cynthia Magro⁸, Richard Granstein⁹, Michelle Lowes¹⁰, Eric Pamer¹¹, Daniel Kaplan¹², Jane E. Salmon^13,14, Babak Mehrara¹⁵, James Young^10,11,16,17, Robert M. Clancy¹⁸, Carl Blobel^14,19,20 and Theresa T. Lu^2,3,21, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, ³Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, ⁴Rheumatology, NYU School of Medicine, New York, NY, ⁵Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ⁸Pathology, Weill Cornell Medicine, New York, NY, ⁹Dermatology, Weill Cornell Medicine, New York, NY, ¹⁰Rockefeller University, New York, NY, ¹¹Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, ¹²Immunology, University of Pittsburgh, New, NY, ¹³Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Weill Cornell Medicine, New York, NY, ¹⁵Plastic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, ¹⁶Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, ¹⁷Medicine, Weill Cornell Medicine, New York, NY, ¹⁸Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ¹⁹Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ²⁰Institute of Advanced Studies, Technical University of Munich, New York, NY, ²¹Autoimmunity and Inflammation Program and Pediatric Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Photosensitivity, or skin sensitivity to ultraviolet radiation (UVR), is a feature of lupus erythematosus (LE) and other autoimmune conditions. Photosensitive lesions can be disfiguring…
Abstract Number: 20 • 2018 ACR/ARHP Annual Meeting
Expression and Functions of the Transcription Factors Ikaros and Aiolos in Sjogren’s Syndrome and Systemic Lupus Erythematosus
Felice Rivellese^1,2, Daniele Mauro¹, Mattia Congia³, Elena Pontarini¹, Peter Schafer⁴, Michele Bombardieri^1,2, Costantino Pitzalis^1,5 and Myles J. Lewis^1,2, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kindgdom, London, United Kingdom, ²Barts Health NHS Trust & Barts and the London School of Medicine & Dentistry, London, United Kingdom, London, United Kingdom, ³Rheumatology and Rheumatology Unit, University Clinic and AOU of Cagliari, Cagliari, Italy, Cagliari, Italy, ⁴Celgene Corporation, Summit, NJ, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Polymorphisms of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for the maturation, differentiation and survival of B cells, have been…
Abstract Number: 715 • 2018 ACR/ARHP Annual Meeting
Septic Shock Among Patients with Systemic Lupus Erythematosus: Short and Long-Term Outcome and Cost. Analysis of the French Nationwide Database
Arthur Mageau¹, Karim Sacre², Anne Perozziello¹, Stephane Ruckly¹, Claire Dupuis¹, Lila Bouadma¹, Thomas Papo¹ and Jean Francois Timsit¹, ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Infection is a leading cause of death and ICU admission in systemic lupus erythematosus (SLE) patients. Our aim was to investigate the outcome and…
Abstract Number: 1084 • 2018 ACR/ARHP Annual Meeting
Dysfunction of the DNASE1L3 Pathway and Antigen Accumulation in Lupus Nephritis
Johannes Hartl¹, Robert M. Clancy¹, Peter M. Izmirly², H. Michael Belmont¹, Nicole Kaiden³, Nicole Bornkamp³, Vanja Sisirak¹, Benjamin Sally¹, Jill P. Buyon¹ and Boris Reizis¹, ¹NYU School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Medicine, NYU School of Medicine, New York, NY
Background/Purpose: DNASE1L3 is a unique secreted DNase that is capable of degrading DNA complexed with proteins and/or encapsulated in membranes, such as chromatin within microparticles…
Abstract Number: 1942 • 2018 ACR/ARHP Annual Meeting
Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus Associate with Decreased White Matter Integrity and Impaired Spatial Memory
Erik Anderson¹, An Vo², Elisabeth Ploran³, Betty Diamond², Bruce Volpe⁴, Cynthia Aranow², David Eidelberg² and Meggan Mackay², ¹Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Hofstra University, Hempstead, NY, ⁴Biomedical Sciences, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment is common in SLE and impacts quality of life; however, causality is limited by incomplete understanding of neurotoxic mechanisms. Diffusion tensor imaging…
Abstract Number: 2150 • 2018 ACR/ARHP Annual Meeting
Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus
Courtney Hoge¹, C. Barrett Bowling², S. Sam Lim³, Cristina Drenkard⁴ and Laura Plantinga⁵, ¹Department of Epidemiology, Emory University, Atlanta, GA, ²Durham Veterans Affairs Medical Center, Durham, NC, ³Emory University School of Medicine, Atlanta, GA, ⁴Medicine/Rheumatology, Emory University, Atlanta, GA, ⁵Department of Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Lower socioeconomic status (SES) has been shown to be associated with poor physical functioning in systemic lupus erythematosus (SLE) patients; however, previous studies have…
Abstract Number: 2894 • 2018 ACR/ARHP Annual Meeting
Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G. Hanly¹, Qiuju Li², Li Su³, Murray Urowitz⁴, Caroline Gordon⁵, Sang-Cheol Bae⁶, Juanita Romero-Díaz⁷, Jorge Sanchez-Guerrero⁴, Sasha Bernatsky⁸, Ann E. Clarke⁹, Daniel J. Wallace¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Joan T. Merrill¹³, Paul R. Fortin¹⁴, Dafna D Gladman¹⁵, Ian N. Bruce¹⁶, Michelle Petri¹⁷, Ellen M. Ginzler¹⁸, Mary Dooley¹⁹, Kristján Steinsson²⁰, Rosalind Ramsey-Goldman²¹, Asad A Zoma²², Susan Manzi²³, Ola Nived²⁴, Andreas Jönsen²⁴, Munther A Khamashta²⁵, Graciela S. Alarcón²⁶, Ronald F van Vollenhoven²⁷, Cynthia Aranow²⁸, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, Manuel Ramos-Casals³⁰, S. Sam Lim³¹, Murat Inanc³², Kenneth C. Kalunian³³, Søren Jacobsen³⁴, Christine A. Peschken³⁵, Diane L. Kamen³⁶, Anca Askanase³⁷, Chris Theriault³⁸ and Vernon Farewell³⁹, ¹Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²MRC Biostatistics Unit, Cambridge, United Kingdom, ³Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴University of Toronto Lupus Research Program, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁸Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁰Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹University College London, London, United Kingdom, ¹²Rayne Institute, University College London, London, United Kingdom, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁷Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹⁹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²⁰Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²¹FSM, Northwestern University, Chicago, IL, ²²Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, East Kilbride, Scotland, United Kingdom, ²³Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Rheumatology, Lund University, Department of Clinical Sciences, Lund, Sweden, ²⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ²⁶University of Alabama at Birmingham, Birmingham, AL, ²⁷Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden, ²⁸The Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³⁰Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ³¹Emory University School of Medicine, Atlanta, GA, ³²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³⁴Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁵RR 149G, University of Manitoba, Winnipeg, MB, Canada, ³⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁷Rheumatology, Columbia University, College of Physician and Surgeons, New York, NY, ³⁸Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ³⁹Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Psychosis, one of the rarer neuropsychiatric (NP) events in lupus patients, features in both the ACR and Systemic Lupus International Collaborating Clinics (SLICC) classification…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.